
Tonix Pharmaceuticals Holding Corp TNXP.OQ TNXP.O is expected to show a rise in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025
The Chatham New Jersey-based company is expected to report a 2.7% increase in revenue to $2.55 million from $2.48 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Tonix Pharmaceuticals Holding Corp is for a loss of $3.23 per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts had fallen by about 31.7% in the last three months.
Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $70.00, above its last closing price of $18.94.
This summary was machine generated May 9 at 21:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)